Market capitalization | $382.41m |
Enterprise Value | $371.49m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 16.41 |
P/S ratio (TTM) P/S ratio | 16.89 |
P/B ratio (TTM) P/B ratio | 39.10 |
Revenue growth (TTM) Revenue growth | 945.91% |
Revenue (TTM) Revenue | $22.64m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Delcath Systems Inc forecast:
7 Analysts have issued a Delcath Systems Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 23 23 |
943%
943%
|
|
Gross Profit | 18 18 |
1,774%
1,774%
|
|
EBITDA | -26 -26 |
23%
23%
|
EBIT (Operating Income) EBIT | -27 -27 |
23%
23%
|
Net Profit | -34 -34 |
24%
24%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Head office | United States |
CEO | Gerard Michel |
Employees | 76 |
Founded | 1988 |
Website | www.delcath.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.